Archive for January 2022
Considerations for Ensuring Optimal Digital Adherence Monitoring
It’s no secret, recruiting clinical trial participants is difficult, time-consuming, and considerably expensive, all while dropout rates are notoriously high across therapeutic areas. Whatever the motive for dropout, the impact is huge. Trials can become underpowered and may not have enough data to effectively demonstrate either statistically significant clinical benefit or the safety of the…
Read MoreMitigating the Risk of Trial Failure with Digital Adherence Monitoring
Drug development is inherently risky, with some analysis showing that just 13.8% of products that enter industry-sponsored Phase I trials go on to obtain FDA approval.1 Of course, the exact figure varies across therapy areas and development stages, but it is an expensive problem no matter how you slice the data. So, what can Sponsors and…
Read MoreAddressing Medication Adherence in Decentralized Clinical Trials
Adherence monitoring can minimize variability and maximize engagement in DCTs Decentralized clinical trials (DCT) are growing in popularity, thanks to their ability to tear down many of the long-standing barriers to robust medical research. And while this new model has some challenges of its own, focusing on adherence can help tackle them head-on. COVID-19 accelerated…
Read MoreImproving Clinical Trial ROI with Medication Adherence Management
Study power is the Holy Grail of clinical trials, setting drug developers on the quickest path to market – but non-adherence causes costly detours. When participants do not take their medication as specified in the study protocol, it can result in underestimated drug efficacy, delay the approval of investigational products, and contribute to rising costs.…
Read More